This activity is no longer available for credit, however its content is still relevant for your educational needs.

Target Audience
This activity was developed for oncology nurses and pharmacists who wish to enhance their knowledge concerning the treatment of patients with metastatic breast cancer (MBC).

Learning Objectives
At the completion of this activity participants should be able to:

• Review the epidemiology and staging of MBC
• Describe current, established therapies for MBC
• Review recent findings on emerging therapies that target intracellular signaling pathways in the treatment of MBC
• Identify common treatment-related toxicities associated with novel therapies for MBC and discuss appropriate management strategies

Disclosure Statement
Before the activity, all faculty will disclose the existence of any financial interest and/or relationship(s) they might have with the manufacturer(s) of any commercial products(s) to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers’ bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions.

The associates of Medical Learning Institute, Inc. have no financial relationships to disclose. The associates of Center of Excellence Media, LLC, have no financial relationships to disclose.

Faculty Disclosures
Laura Boehnke Michaud, PharmD, BCOP, FASHP is on the speaker's bureau for GlaxoSmithKline, and is on the advisory board for Prostrakan.

Carrie Tompkins Stricker, PhD, RN, AOCN is on the speaker's bureau for Merck and Roche.

Jennie Lattimer, MSN, CRNP, AOCN has nothing to disclose.


*Content will include non-FDA-approved uses.

Disclaimer
The information provided in this CE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition.